TP53 and non-small cell lung carcinoma: More gene mutations are superior than TMB-H in predicting response to pembrolizumab with NSCLC.102 Recurrent somatic mutations of BCLAF1, KRAS, BRAF, and P53, as well as MAPK signalling and p53-associated pathways, are predictors of ICB response.103 Metabolic dysregulation in tumour cells also has a great impact on the efficacy of immunotherapy.